Stock Ratings / Health Care / CMPS / insiders

ANIP (70) STOK (59) NUVB (29) NBTX (52) ⌘ Pro Terminal →

COMPASS Pathways Plc American Depository Shares (CMPS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$12.19 -0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.15

COMPASS Pathways Plc American Depository Shares (CMPS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.69B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.15 (-0.32%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CMPS)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY CMPS SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.00-10.4% Next Q

Q2 (-2Q)

Grade E$10.75+4% Next Q

Q3 (-1Q)

Grade E$11.18+9% Next Q

Current

Grade D-$12.19-8.1% Hist 90D α

Trajectory: E (29) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CMPS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CMPS currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.91) and Max Pain ($12.80) forces dealer call-delta covering toward $16.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CMPS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CMPS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CMPS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CMPS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CMPS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CMPS)

✓Walkthrough of CMPS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CMPS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.55%📐 HORIZONTAL RANGE

2026-10-30O $11.82H $12.19L $11.27C $12.19VOL 2.17M

RES: $16.22SUP: $10.74SMA50: $12.91SMA200: $10.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CMPS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CMPS Butterfly Map → + Track CMPS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CMPS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CMPS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CMPS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CMPS)

Health Care Rank #739 of 1016 ⚔️ ANIP vs CMPS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CMPS vs. ANIP, STOK, NUVB, NBTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, COMPASS Pathways Plc American Depository Shares (CMPS) ranks #739 by composite RQD confidence (37/100, grade D-) and #288 by equity capitalization ($1.69B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with CMPS at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CMPS ACTIVE COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	Benchmark Subject
ANIP ANI Pharmaceuticals Inc.	B-	70/100	21.5x	—	16.0%	+2.02%	$1.68B	/anip-vs-cmps →
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-cmps →
NUVB Nuvation Bio Inc. (Class A)	E	29/100	—	—	-35.0%	+3.92%	$1.67B	/nuvb-vs-cmps →
NBTX Nanobiotix S.A.	D+	52/100	—	—	—	-0.53%	$1.72B	/nbtx-vs-cmps →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001816590

In its most recent audited fiscal period (FY2025, filed 2025-12-31), COMPASS Pathways Plc American Depository Shares (CMPS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$269.8M, operating cash flow of -$157.2M, and free cash flow of -$157.2M (-31.9% YoY). On the balance sheet, CMPS closed FY2025 with $210.3M in total assets against $14.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$269.8M	-$157.2M	-$157.2M	$210.3M	$14.1M
FY2024 (FY)	2024-12-31	$0	-$155.1M	-$119.2M	-$119.2M	$213.7M	$24.7M
FY2023 (FY)	2023-12-31	$0	-$118.5M	-$97.4M	-$97.4M	—	—

3. CMPS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CMPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, COMPASS Pathways Plc American Depository Shares (NASDAQ: CMPS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $12.19 (-0.73% 1D, market cap $1.69B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CMPS ranks #739 in composite RQD confidence.

How does CMPS compare to ANIP and STOK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMPS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIP (ANI Pharmaceuticals Inc.) holds a B- grade (70/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.68B) and STOK (Stoke Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -6.1%, cap $1.70B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CMPS?

Per CMPS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816590), COMPASS Pathways Plc American Depository Shares generated $0 in revenue, -$269.8M in net income, and -$157.2M in free cash flow against $210.3M in total assets and $14.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CMPS trading relative to its 50-day, 200-day, and 52-week technical levels?

CMPS last traded at $12.19 (-0.73% on volume of 1,382,444 shares), positioning the stock -5.58% below its 50-day simple moving average ($12.91) and +17.21% above its 200-day simple moving average ($10.40). Across its 52-week range of $4.88 to $15.87, CMPS sits at the 66.5% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($10.81 to $13.57).

CMPS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CMPS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CMPS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CMPS RQD Cockpit CMPS 12M Forecast CMPS Earnings & Move CMPS Dividends & DRIP CMPS Insiders & 13F CMPS Whale Options CMPS Profit Sankey CMPS News & Why